Nianli Liu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2683170/publications.pdf

Version: 2024-02-01

24 papers	601 citations	623734 14 h-index	642732 23 g-index
25 all docs	25 docs citations	25 times ranked	1019 citing authors

#	Article	IF	Citations
1	Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	0
2	SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer. Medical Oncology, 2021, 38, 57.	2.5	8
3	Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles. Artificial Cells, Nanomedicine and Biotechnology, 2020, 48, 305-314.	2.8	11
4	MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 10001-10012.	2.0	7
5	SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26. Cell Death and Disease, 2019, 10, 667.	6.3	36
6	ISG12a and its interaction partner NR4A1 are involved in TRAILâ€induced apoptosis in hepatoma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 3520-3529.	3.6	11
7	Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses. Molecular Cancer Therapeutics, 2019, 18, 323-334.	4.1	24
8	Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-ƙB and L1CAM activities. Pancreatology, 2018, 18, 328-333.	1.1	32
9	H1/<scp>pAIM</scp>2 nanoparticles exert antiâ€tumour effects that is associated with the inflammasome activation in renal carcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 5670-5681.	3.6	17
10	Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1309-1321.	3.3	28
11	Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin Î±vÎ²3/FAK/PI3K pathway-mediated Rac1 activation. Journal of Biosciences, 2017, 42, 491-499.	1.1	15
12	Isolation and comparison of mesenchymal stem cell-like cells derived from human gastric cancer tissues and corresponding ovarian metastases. Molecular Medicine Reports, 2016, 13, 1788-1794.	2.4	9
13	Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Cancer Letters, 2016, 379, 213-219.	7.2	52
14	ISG12a Restricts Hepatitis C Virus Infection through the Ubiquitination-Dependent Degradation Pathway. Journal of Virology, 2016, 90, 6832-6845.	3.4	47
15	Interferon-Î± and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma. Experimental Cell Research, 2015, 333, 316-326.	2.6	14
16	Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells. FEBS Letters, 2015, 589, 897-903.	2.8	11
17	MiR-942 Mediates Hepatitis C Virus-Induced Apoptosis via Regulation of ISG12a. PLoS ONE, 2014, 9, e94501.	2.5	30
18	miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget, 2014, 5, 4959-4971.	1.8	54

#	Article	IF	Citations
19	Inhibition of Hepatitis C Virus Infection by DNA Aptamer against NS2 Protein. PLoS ONE, 2014, 9, e90333.	2.5	23
20	Inhibition of hepatitis C virus infection by NS5A-specific aptamer. Antiviral Research, 2014, 106, 116-124.	4.1	21
21	Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1264-73.	7.1	88
22	ISG12a mediates cell response to Newcastle disease viral infection. Virology, 2014, 462-463, 283-294.	2.4	24
23	2-Octynoic Acid Inhibits Hepatitis C Virus Infection through Activation of AMP-Activated Protein Kinase. PLoS ONE, 2013, 8, e64932.	2.5	12
24	Innate Host Response in Primary Human Hepatocytes with Hepatitis C Virus Infection. PLoS ONE, 2011, 6, e27552.	2.5	27